LA
ORIAU

Linden Advisors’s Orion Biotech Opportunities Corp. Units ORIAU Stock Holding History

Linden Advisors’s Portfolio ORIAU Stock Details ORIAU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-700,000
Closed -$6.93M – 843
2021
Q4 		$6.93M Hold
700,000
– – 0.04% 234
2021
Q3 		$6.93M Hold
700,000
– – 0.04% 244
2021
Q2 		$7.04M Buy
+700,000
New +$7.05M 0.04% 255

Other funds holding ORIAU

JP
JNE Partners London, United Kingdom $244M AUM 15.73% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
SMA
Sage Mountain Advisors Atlanta, Georgia $1.43B AUM 16.47% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Linden Advisors's ORIAU Position: Q1 2022 in Review

Linden Advisors sold out of Orion Biotech Opportunities Corp. Units (ORIAU) in Q1 2022, closing a stake of 700,000 shares — an estimated $6.93M sold.

Linden Advisors first reported a position in ORIAU in Q2 2021 and held it in 3 quarters. The position peaked at $7.04M in Q2 2021. 14 funds tracked by Wall St. Rank hold ORIAU as of Q1 2022.

  • Linden Advisors reported no remaining Orion Biotech Opportunities Corp. Units position as of Q1 2022 after selling out during the quarter.
  • Linden Advisors sold 700,000 Orion Biotech Opportunities Corp. Units shares in Q1 2022, an estimated $6.93M.
  • Linden Advisors first reported a position in Orion Biotech Opportunities Corp. Units in Q2 2021 and held it in 3 quarters.
  • Linden Advisors's Orion Biotech Opportunities Corp. Units position peaked at $7.04M in Q2 2021.
  • 14 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Units as of Q1 2022.

Based on Linden Advisors's 13F filing for Q1 2022, filed 16 May 2022.